Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Angela M. H. Brodie"'
Publikováno v:
Cancer research. 68(12)
Using the intratumoral aromatase xenograft model, we have observed that despite long-lasting growth inhibition, tumors eventually begin to grow during continued letrozole treatment. In cells isolated from these long-term letrozole-treated tumors (LTL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c0ed03197740d3112dec56bac55346
https://pubmed.ncbi.nlm.nih.gov/18559495
https://pubmed.ncbi.nlm.nih.gov/18559495
Autor:
James N. Ingle, Luciana Macedo, Danijela Jelovac, Brian J. Long, Venkatesh D. Handratta, Angela M. H. Brodie, Olga Goloubeva
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(21)
Purpose: To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmeno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f687efb809ff42fd139eb74476e8f5
https://pubmed.ncbi.nlm.nih.gov/15534114
https://pubmed.ncbi.nlm.nih.gov/15534114
Autor:
Angela M. H. Brodie
Publikováno v:
Breast Cancer ISBN: 9780429221712
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e91e252b95704c3750ef334d43c7d4ed
https://doi.org/10.3109/9780203909249-11
https://doi.org/10.3109/9780203909249-11
Autor:
Angela M. H. Brodie
Publikováno v:
Hormones and Cancer ISBN: 9781461287155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08b9b6bfbfcaa5efd335e9999986b807
https://doi.org/10.1007/978-1-4612-4266-6_12
https://doi.org/10.1007/978-1-4612-4266-6_12
Autor:
Rabia A. Gilani, Vincent C. O. Njar, Olga Goloubeva, Angela M. H. Brodie, Lalji K. Gediya, Gauri Sabnis, Luciana Macedo
Publikováno v:
Cancer Research. 69:6128
Abstract #6128 It is well established that approximately 75% of human breast cancers are ER+ and therefore treated with endocrine therapy. In a past few decades endocrine therapy has made significant advancements. However, the application of these ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0911e84a3df464f06baa90d09fe3253c
https://doi.org/10.1158/0008-5472.sabcs-6128
https://doi.org/10.1158/0008-5472.sabcs-6128